Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31573596 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1MAPTHSD17B10POLB | |
| SCHEMBL31598671 | 0.84 | CHEK1 (0.46) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL29574609 | 0.80 | BAZ2B (0.51) | KDM4EALDH1A1MAPTBAZ2BBAZ2A | |
| SCHEMBL190973 | 0.80 | BAZ2B (0.51) | KDM4EALDH1A1MAPTBAZ2BBAZ2A | |
| SCHEMBL3652621 | 0.80 | BAZ2B (0.51) | KDM4EALDH1A1MAPTBAZ2BBAZ2A | |
| SCHEMBL22717808 | 0.80 | POLB (0.52) | ALDH1A1POLBL3MBTL1TDP1KMT2A | |
| SCHEMBL29574677 | 0.80 | POLB (0.52) | ALDH1A1POLBL3MBTL1TDP1KMT2A | |
| SCHEMBL16580957 | 0.78 | BAZ2B (0.49) | KDM4EALDH1A1MAPTBAZ2BBAZ2A | |
| SCHEMBL22990213 | 0.77 | CHEK1 (0.46) | KDM4EALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL22717325 | 0.77 | BAZ2B (0.48) | KDM4EALDH1A1MAPTHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2025-05-01 | — | — | US | disclosed |
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-04-17 | — | — | US | disclosed |
| CN-119504705-A | Non-peptide somatostatin 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114585614-B | Non-peptide somatostatin 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4464709-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-118525025-A | Six-membered cyclothiazole compound and application thereof | 南京再明医药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023134739-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | 南京再明医药有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| EP-4013748-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114585614-A | Non-peptide somatostatin type 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
| WO-2021030262-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885MAPT 3785/4885 |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885MAPT 3785/4885 |
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | POLRMT, POLQ, POLH | KDM4E 2890/4885ALDH1A1 1554/4885MAPT 99/4885 |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885MAPT 3785/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885MAPT 3785/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | KDM4E 1542/4885ALDH1A1 4138/4885MAPT 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.